Investigational Treatment Shows Superiority in RA Study

Investigational Treatment Shows Superiority in RA Study

Regeneron and Sanofi announced their Phase 3 study for sarilumab has met its primary endpoint, demonstrating superiority over adalimumab in improving symptoms in patients with active rheumatoid arthritis (RA) at Week 24, in the SARIL-RA-MONARCH …

(Visited 3 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.